The expected signs and symptoms with overdosage of Стриверди Респимат are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., myocardial ischemia, angina pectoris, hypertension or hypotension, tachycardia, arrhythmias, palpitations, dizziness, nervousness, insomnia, anxiety, headache, tremor, dry mouth, muscle spasms, nausea, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of Стриверди Респимат.
Treatment of overdosage consists of discontinuation of Стриверди Респимат together with institution of appropriate symptomatic and supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Стриверди Респимат. Cardiac monitoring is recommended in cases of overdosage.
All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication. Стриверди Респимат is not indicated for the treatment of asthma.
Long-acting beta2-adrenergic agonists, such as STRIVERDI RESPIMAT, increase the risk of asthma-related death. Стриверди Респимат is not indicated for the treatment of asthma.
Clinical Trials Experience In Chronic Obstructive Pulmonary DiseaseBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The Стриверди Респимат clinical development program included seven dose-ranging trials and eight confirmatory trials. Four of the confirmatory trials were 6week cross-over trials and four were 48-week parallel group trials. Adverse reactions observed in the dose-ranging trials and four 6-week cross-over trials were consistent with those observed in the 48-week parallel group trials, which formed the primary safety database.
The primary safety database consisted of pooled data from the four 48-week double-blind, active and placebo-controlled, parallel group confirmatory clinical trials. These trials included 3104 adult COPD patients (77% males and 23% females) 40 years of age and older. Of these patients, 876 and 883 patients were treated with Стриверди Респимат 5 mcg and 10 mcg once-daily, respectively. The Стриверди Респимат groups were composed of mostly Caucasians (66%) with a mean age of 64 years and a mean percent predicted FEV1 at baseline of 44% for both the 5 mcg and 10 mcg treatment groups. Control arms for comparison included placebo in all four trials plus formoterol 12 mcg in two trials.
In these four clinical trials, seventy-two percent (72%) of patients exposed to any dose of Стриверди Респимат reported an adverse reaction compared to 71% in the placebo group. The proportion of patients who discontinued due to an adverse reaction was 7.2% for Стриверди Респимат treated patients compared to 8.8% for placebo treated patients. The adverse reaction most commonly leading to discontinuation was worsening COPD. The most common serious adverse reactions were COPD exacerbation, pneumonia, and atrial fibrillation.
Table 1 shows all adverse drug reactions reported by at least 2% of patients (and higher than placebo) who received Стриверди Респимат 5 mcg during the 48week trials.
Table 1 : Number and frequency of adverse drug reactions greater than 2% (and higher than placebo) in COPD patients exposed to Стриверди Респимат 5 mcg: Pooled data from the four 48-week, double-blind, active- and placebo-controlled clinical trials in COPD patients 40 years of age and older
| Treatment | STRIVERDI 5 mcg once-daily | Placebo |
| Body system (adverse drug reaction) | n=876 n (%) | n=885 n (%) |
| Infections and infestations | ||
| Nasopharyngitis | 99 (11.3) | 68 (7.7) |
| Upper Respiratory Tract Infection | 72 (8.2) | 66 (7.5) |
| Bronchitis | 41 (4.7) | 32 (3.6) |
| Urinary Tract Infection | 22 (2.5) | 9 (1.0) |
| Respiratory, thoracic, and mediastinal disorders | ||
| Cough | 37 (4.2) | 35 (4.0) |
| Nervous system disorders | ||
| Dizziness | 20 (2.3) | 19 (2.1) |
| Skin and subcutaneous tissue disorders | ||
| Rash* | 19 (2.2) | 10 (1.1) |
| Gastrointestinal disorders | ||
| Diarrhea | 25 (2.9) | 22 (2.5) |
| Musculoskeletal and connective tissue disorders | ||
| Back Pain | 31 (3.5) | 24 (2.7) |
| Arthralgia | 18 (2.1) | 7 (0.8) |
| * Rash includes a grouping of similar terms. | ||
Additional adverse reactions that occurred in greater than 2% (and higher than placebo) of patients exposed to Стриверди Респимат 10 mcg were pneumonia, constipation, and pyrexia.
Lung cancers were reported in 6 (0.7%), 3 (0.3%), and 2 (0.2%) patients who received Стриверди Респимат 10 mcg, 5 mcg, and placebo, respectively.
Стриверди Респимат is a long-acting beta2-agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Important Limitations Of UseСтриверди Респимат is not indicated to treat acute deteriorations of COPD.
Стриверди Респимат is not indicated to treat asthma. The safety and effectiveness of Стриверди Респимат in asthma have not been established.
The major adverse effects of inhaled beta2-adrenergic agonists occur as a result of excessive activation of systemic beta-adrenergic receptors. The most common adverse effects in adults include skeletal muscle tremor and cramps, insomnia, tachycardia, decreases in serum potassium, and increases in plasma glucose.
Changes in serum potassium were evaluated in COPD patients in double-blind phase 3 studies. In pooled data, at the recommended 5 mcg dose there was no clinically relevant change compared to placebo in serum potassium.
ElectrophysiologyThe effect of Стриверди Респимат on the QT/QTc interval of the ECG was investigated in 24 healthy male and female volunteers in a double-blind, randomized, placebo- and active (moxifloxacin)-controlled study at single doses of 10, 20, 30, and 50 mcg. Dose-dependent QTcI (individual subject corrected QT interval) prolongation was observed. The maximum mean (one-sided 95% upper confidence bound) difference in QTcI from placebo after baseline correction was 2.5 (5.6) ms, 6.1 (9.2) ms, 7.5 (10.7) ms and 8.5 (11.6) ms following doses of 10, 20, 30 and 50 mcg, respectively.
The effect of 5 mcg and 10 mcg Стриверди Респимат on heart rate and rhythm was assessed using continuous 24-hour ECG recording (Holter monitoring) in a subset of 772 patients in the 48-week, placebo-controlled phase 3 trials. There were no dose-or time-related trends or patterns observed for the magnitudes of mean changes in heart rate or premature beats. Shifts from baseline to the end of treatment in premature beats did not indicate meaningful differences between Стриверди Респимат 5 mcg, 10 mcg, and placebo.
Olodaterol showed linear pharmacokinetics. On repeated once-daily inhalation steady-state of olodaterol plasma concentrations was achieved after 8 days, and the extent of exposure was increased up to 1.8-fold as compared to a single dose.
AbsorptionOlodaterol reaches maximum plasma concentrations generally within 10 to 20 minutes following drug inhalation. In healthy volunteers, the absolute bioavailability of olodaterol following inhalation was estimated to be approximately 30%, whereas the absolute bioavailability was below 1% when given as an oral solution. Thus, the systemic availability of olodaterol after inhalation is mainly determined by lung absorption, while any swallowed portion of the dose only negligibly contributes to systemic exposure.
DistributionOlodaterol exhibits multi-compartmental disposition kinetics after inhalation as well as after intravenous administration. The volume of distribution is high (1110 L), suggesting extensive distribution into tissue. In vitro binding of [14C] olodaterol to human plasma proteins is independent of concentration and is approximately 60%.
MetabolismOlodaterol is substantially metabolized by direct glucuronidation and by O-demethylation at the methoxy moiety followed by conjugation. Of the six metabolites identified, only the unconjugated demethylation product binds to beta2-receptors. This metabolite, however, is not detectable in plasma after chronic inhalation of the recommended therapeutic dose.
Cytochrome P450 isozymes CYP2C9 and CYP2C8, with negligible contribution of CYP3A4, are involved in the O-demethylation of olodaterol, while uridine diphosphate glycosyl transferase isoforms UGT2B7, UGT1A1, 1A7, and 1A9 were shown to be involved in the formation of olodaterol glucuronides.
EliminationTotal clearance of olodaterol in healthy volunteers is 872 mL/min, and renal clearance is 173 mL/min. The terminal half-life following intravenous administration is 22 hours. The terminal half-life following inhalation in contrast is about 45 hours, indicating that the latter is determined by absorption rather than by elimination processes. However, the effective half-life at daily dose of 5 μg calculated from Cmax from COPD patients is 7.5 hours.
Following intravenous administration of [14C]-labeled olodaterol, 38% of the radioactive dose was recovered in the urine and 53% was recovered in feces. The amount of unchanged olodaterol recovered in the urine after intravenous administration was 19%. Following oral administration, only 9% of olodaterol and/or its metabolites was recovered in urine, while the major portion was recovered in feces (84%). More than 90% of the dose was excreted within 6 and 5 days following intravenous and oral administration, respectively. Following inhalation, excretion of unchanged olodaterol in urine within the dosing interval in healthy volunteers at steady state accounted for 5% to 7% of the dose.
Included as part of the PRECAUTIONS section.
PRECAUTIONS Asthma-Related DeathСтриверди Респимат should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. Стриверди Респимат has not been studied in patients with acutely deteriorating COPD. The use of Стриверди Респимат in this setting is inappropriate.
Стриверди Респимат should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Стриверди Респимат has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.
When beginning Стриверди Респимат, patients who have been taking inhaled, short-acting beta2-agonists on a regular basis (e.g., four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms. When prescribing Стриверди Респимат, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient on how it should be used. Increasing inhaled beta2-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated.
COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If Стриверди Респимат no longer controls symptoms of bronchoconstriction, or the patient's inhaled, short-acting beta2-agonist becomes less effective or the patient needs more inhalation of short-acting beta2-agonist than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dosage of Стриверди Респимат beyond the recommended dose is not appropriate in this situation.
Excessive Use Of Стриверди Респимат And Use With Long-Acting Beta2-AgonistsAs with other inhaled drugs containing beta2-adrenergic agents, Стриверди Респимат should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications containing long-acting beta2-agonists, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.
Paradoxical BronchospasmAs with other inhaled beta2-agonists, Стриверди Респимат may produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, Стриверди Респимат should be discontinued immediately and alternative therapy instituted.
Cardiovascular EffectsСтриверди Респимат, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and/or symptoms. If such effects occur, Стриверди Респимат may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Long acting beta2-adrenergic agonists should be administered with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, and hypertension.
Co-existing ConditionsСтриверди Респимат, like other sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis, in patients with known or suspected prolongation of the QT interval, and in patients who are unusually responsive to sympathomimetic amines. Doses of the related beta2-agonist albuterol, when administered intravenously, have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis.
Hypokalemia And HyperglycemiaBeta-adrenergic agonists may produce significant hypokalemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. Inhalation of high doses of beta2-adrenergic agonists may produce increases in plasma glucose.
In patients with severe COPD, hypokalemia may be potentiated by hypoxia and concomitant treatment , which may increase the susceptibility for cardiac arrhythmias.
Clinically notable decreases in serum potassium or changes in blood glucose were infrequent during clinical studies with long-term administration of Стриверди Респимат with the rates similar to those for placebo controls. Стриверди Респимат has not been investigated in patients whose diabetes mellitus is not well controlled.
Hypersensitivity ReactionsImmediate hypersensitivity reactions, including angioedema, may occur after administration of Стриверди Респимат. If such a reaction occurs, therapy with Стриверди Респимат should be stopped at once and alternative treatment should be considered.
Patient Counseling InformationSee FDA-Approved Patient Labeling (Medication Guide and Instructions for Use).
Asthma-Related DeathInform patients that LABA, such as Стриверди Респимат, increase the risk of asthma-related death. STRIVERDI RESPIMAT is not indicated for the treatment of asthma.
Preparation For Use And PrimingInstruct patients that priming Стриверди Респимат is essential to ensure appropriate content of the medication in each actuation.
When using the unit for the first time, the Стриверди Респимат cartridge is inserted into the STRIVERDI RESPIMAT inhaler and the unit is primed. Стриверди Респимат patients are to actuate the inhaler toward the ground until an aerosol cloud is visible and then repeat the process three more times. The unit is then considered primed and ready for use. If not used for more than 3 days, patients are to actuate the inhaler once to prepare the inhaler for use. If not used for more than 21 days, patients are to actuate the inhaler until an aerosol cloud is visible and then repeat the process three more times to prepare the inhaler for use.
Not For Acute SymptomsСтриверди Респимат is not meant to relieve acute asthma symptoms or exacerbations of COPD and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist such as albuterol. (The healthcare provider should provide the patient with such medication and instruct the patient in how it should be used.)
Instruct patients to notify their physician immediately if they experience any of the following:
Instruct patients not to stop therapy with Стриверди Респимат without physician/provider guidance since symptoms may recur after discontinuation.
Do Not Use Additional Long-Acting Beta2-AgonistsPatients who have been taking inhaled, short-acting beta2-agonists on a regular basis should be instructed to discontinue the regular use of these products and use them only for the symptomatic relief of acute symptoms.
When patients are prescribed Стриверди Респимат, other inhaled medications containing long-acting beta2-agonists should not be used. Patients should not use more than the recommended once-daily dose of Стриверди Респимат. Excessive use of sympathomimetics may cause significant cardiovascular effects, and may be fatal.
Risks Associated With Beta2-Agonist TherapyInform patients of adverse effects associated with beta2-agonists, such as palpitations, chest pain, rapid heart rate, tremor, or nervousness.
Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment Of FertilityTwo-year inhalation studies were conducted in rats and mice to assess the carcinogenic potential of olodaterol. Lifetime treatment of female rats induced leiomyomas of the mesovarium at doses of 25.8 and 270 mcg/kg/day (approximately 18- and 198-fold, respectively, the MRHDID on an AUC basis). No tumor findings were observed in male rats at doses up to 270 mcg/kg/day (approximately 230-fold the MRHDID on an AUC basis). Lifetime treatment of female mice induced leiomyomas and leiomyosarcomas of the uterus at doses ≥ 76.9 mcg/kg/day (approximately 106-fold the MRHDID on an AUC basis). No tumor findings were observed in male mice at doses up to 255 mcg/kg/day (approximately 455-fold the MRHDID on an AUC basis). Increases in leiomyomas and leiomyosarcomas of the female rodent reproductive tract have been similarly demonstrated with other β2-adrenergic agonist drugs. The relevance of these findings to human use is unknown.
Olodaterol was not mutagenic in the in vitro Ames test or in the in vitro mouse lymphoma assay. Olodaterol produced increased frequency of micronuclei in rats after intravenous doses. The increased frequency of micronuclei was likely related to drug enhanced (compensatory) erythropoiesis. The mechanism for induction of micronuclei formation is likely not relevant at clinical exposures.
Olodaterol did not impair male or female fertility in rats at inhalation doses up to 3,068 mcg/kg/day (approximately 2,322 times the MRHDID on an AUC basis).
Use In Specific Populations Pregnancy Teratogenic EffectsPregnancy Category C.
There are no adequate and well-controlled studies with Стриверди Респимат in pregnant women. Стриверди Респимат should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Стриверди Респимат was not teratogenic in rats at inhalation doses approximately 2,731 times the maximum recommended human daily inhalation dose (MRHDID) on an AUC basis (at a rat maternal inhalation dose of 1,054 mcg/kg/day). Placental transfer of Стриверди Респимат was observed in pregnant rats.
Стриверди Респимат has been shown to be teratogenic in New Zealand rabbits at inhalation doses approximately 7,130 times the MRHDID in adults on an AUC basis (at a rabbit maternal inhalation dose of 2,489 mcg/kg/day). Стриверди Респимат exhibited the following fetal toxicities: enlarged or small heart atria or ventricles, eye abnormalities, and split or distorted sternum. No significant effects occurred at an inhalation dose approximately 1,353 times the MRHDID in adults on an AUC basis (at a rabbit maternal inhalation dose of 974 mcg/kg/day).
Labor And DeliveryThere are no adequate and well-controlled human studies that have investigated the effects of Стриверди Респимат on preterm labor or labor at term. Because of the potential for beta-agonist interference with uterine contractility, use of Стриверди Респимат during labor should be restricted to those patients in whom the benefits clearly outweigh the risks.
Nursing MothersOlodaterol, the active component of Стриверди Респимат, and/or its metabolites are excreted into the milk of lactating rats. Excretion of olodaterol and/or its metabolites into human milk is probable. There are no human studies that have investigated the effects of Стриверди Респимат on nursing infants. Caution should be exercised when Стриверди Респимат is administered to nursing women.
Pediatric UseСтриверди Респимат is not indicated for use in children. The safety and effectiveness of Стриверди Респимат in the pediatric population have not been established.
Geriatric UseBased on available data, no adjustment of STRIVERDI RESPIMAT dosage in geriatric patients is necessary.
Of the 876 patients who received Стриверди Респимат at the recommended dose of 5 mcg once-daily in the clinical studies from the pooled 1-year database, 485 were less than or equal to 65 years of age and 391 (44.6%) were greater than 65 years of age.
No overall differences in effectiveness were observed, and in the 1-year pooled data, the adverse drug reaction profiles were similar in the older population compared to the patient population overall.
Hepatic ImpairmentSubjects with mild and moderate hepatic impairment showed no changes in Cmax or AUC, nor did protein binding differ between mild and moderate hepatically impaired subjects and their healthy controls. A study in subjects with severe hepatic impairment was not performed.
Renal ImpairmentSubjects with severe renal impairment showed no clinically relevant changes in Cmax or AUC compared to their healthy controls.
The recommended dose of Стриверди Респимат is two inhalations once-daily at the same time of the day. Do not use STRIVERDI RESPIMAT more than two inhalations every 24 hours.
Prior to first use, the Стриверди Респимат cartridge is inserted into the Стриверди Респимат inhaler and the unit is primed. When using the unit for the first time, patients are to actuate the inhaler toward the ground until an aerosol cloud is visible and then repeat the process three more times. The unit is then considered primed and ready for use. If not used for more than 3 days, patients are to actuate the inhaler once to prepare the inhaler for use. If not used for more than 21 days, patients are to actuate the inhaler until an aerosol cloud is visible and then repeat the process three more times to prepare the inhaler for use.
No dosage adjustment is required for geriatric patients, patients with mild and moderate hepatic impairment, or renally-impaired patients. There are no data available for use of Стриверди Респимат in severe hepatically impaired patients.
